De novo Inflammatory Bowel Disease following Liver and Heart Transplantation: A Case Series Exploring the Role of IL-23 Pathway-Targeted Therapy - PubMed
5 days ago
- #Inflammatory Bowel Disease
- #Organ Transplantation
- #IL-23 Pathway
- De novo inflammatory bowel disease (IBD) is a rare but significant complication after solid organ transplantation (SOT).
- Six cases of de novo IBD (3 liver, 3 heart transplant recipients) were studied, with onset a median of 47.5 months post-transplant.
- Cases included ulcerative colitis-type (UC-type) and Crohn's disease-like (CD-like) IBD, with no pre-transplant intestinal symptoms.
- Alternative etiologies like cytomegalovirus colitis and drug-induced colitis were excluded.
- Treatments included corticosteroids and IL-23 pathway-targeted biologics (mirikizumab, ustekinumab, risankizumab).
- Corticosteroids induced remission in 2 UC-type cases; IL-23-targeted biologics showed efficacy in steroid-refractory and CD-like cases.
- No severe adverse events, opportunistic infections, or graft rejection were observed with IL-23 inhibitors.
- IL-23 pathway inhibitors demonstrated favorable efficacy and safety in SOT recipients with de novo IBD.